• Edoxaban does not impact outcomes after TAVR vs. DAPT

    7 days ago - By Healio

    WASHINGTON - In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve leaflet thrombosis compared with dual antiplatelet therapy.
    There was also no difference between the edoxaban and DAPT groups in cerebral thromboembolism and neurological or neurocognitive function, according to the results, which were presented at the American College of Cardiology Scientific Session and simultaneously published in Circulation.
    The researchers randomly assigned 235 patients who
    Read more ...